CA2726804C - Xbp1, cd138, and cs1 peptides - Google Patents

Xbp1, cd138, and cs1 peptides Download PDF

Info

Publication number
CA2726804C
CA2726804C CA2726804A CA2726804A CA2726804C CA 2726804 C CA2726804 C CA 2726804C CA 2726804 A CA2726804 A CA 2726804A CA 2726804 A CA2726804 A CA 2726804A CA 2726804 C CA2726804 C CA 2726804C
Authority
CA
Canada
Prior art keywords
peptide
seq
peptides
composition
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2726804A
Other languages
English (en)
French (fr)
Other versions
CA2726804A1 (en
Inventor
Nikhil C. Munshi
Kenneth C. Anderson
Jooeun Bae
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Priority to CA3138282A priority Critical patent/CA3138282A1/en
Publication of CA2726804A1 publication Critical patent/CA2726804A1/en
Application granted granted Critical
Publication of CA2726804C publication Critical patent/CA2726804C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70507—CD2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4261—Proteoglycans, e.g. glypican, brevican or CSPG4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2726804A 2008-06-02 2009-06-01 Xbp1, cd138, and cs1 peptides Active CA2726804C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3138282A CA3138282A1 (en) 2008-06-02 2009-06-01 Xbp1, cd138, and cs1 peptides

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5818008P 2008-06-02 2008-06-02
US61/058,180 2008-06-02
PCT/US2009/045866 WO2009149021A2 (en) 2008-06-02 2009-06-01 Xbp1, cd138, and cs1 peptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3138282A Division CA3138282A1 (en) 2008-06-02 2009-06-01 Xbp1, cd138, and cs1 peptides

Publications (2)

Publication Number Publication Date
CA2726804A1 CA2726804A1 (en) 2009-12-10
CA2726804C true CA2726804C (en) 2021-12-28

Family

ID=41398806

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2726804A Active CA2726804C (en) 2008-06-02 2009-06-01 Xbp1, cd138, and cs1 peptides
CA3138282A Pending CA3138282A1 (en) 2008-06-02 2009-06-01 Xbp1, cd138, and cs1 peptides

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3138282A Pending CA3138282A1 (en) 2008-06-02 2009-06-01 Xbp1, cd138, and cs1 peptides

Country Status (6)

Country Link
US (3) US9096681B2 (OSRAM)
EP (2) EP2300034B1 (OSRAM)
JP (7) JP2011523560A (OSRAM)
CN (1) CN102112147B (OSRAM)
CA (2) CA2726804C (OSRAM)
WO (1) WO2009149021A2 (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011523560A (ja) 2008-06-02 2011-08-18 ダナ−ファーバー キャンサー インスティテュート インク． Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド
CN105377288B (zh) * 2012-11-05 2019-11-15 达纳-法伯癌症研究所股份有限公司 Xbp1、cd138和cs1肽的组合物制备药物的用途
ES2820729T3 (es) * 2013-02-15 2021-04-22 Univ Johns Hopkins Redirectores de células T específicas de antígenos
WO2016049022A1 (en) * 2014-09-23 2016-03-31 Board Of Trustees Of Michigan State University Compositions and methods for modulating an immune response
DE102017207683A1 (de) 2016-05-09 2017-11-09 Nichia Corporation Verfahren zur Herstellung eines Nickel-Kobalt-Verbundhydroxids und Verfahren zur Herstellung eines Aktivmaterials einer Positivelektrode für eine wasserfreie Elektrolytsekundärbatterie
CN106093393A (zh) * 2016-06-02 2016-11-09 滨州医学院 一种基于XBP1和XBP1s表达水平的检测胃癌组织的试剂盒
CA3079422A1 (en) 2017-10-24 2019-05-02 Oncopep, Inc. Peptide vaccines and pembrolizumab for treating breast cancer
CN115040663B (zh) * 2022-06-15 2023-12-12 上海交通大学医学院附属仁济医院 溶质载体家族38成员2在制备多发性骨髓瘤治疗药物中的应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4407957A (en) 1981-03-13 1983-10-04 Damon Corporation Reversible microencapsulation of a core material
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4929555A (en) 1987-10-19 1990-05-29 Phillips Petroleum Company Pichia transformation
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
DK0585368T3 (da) 1991-04-25 1998-03-16 Univ Brown Res Found Implanterbart biokompatibelt immunisolatorisk vehikel til afgivelse af udvalgte terapeutiske produkter
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
CA2142007C (en) 1992-08-11 2007-10-30 Robert Glen Urban Immunomodulatory peptides
DK0678122T3 (da) 1993-01-12 2000-03-06 Biogen Inc Rekombinante anti-VLA4 antistofmolekyler
DE19541844C1 (de) 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
US7026443B1 (en) 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
AU6802801A (en) * 2000-03-01 2001-09-24 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
US20020164346A1 (en) 2001-02-14 2002-11-07 Nicolette Charles A. Altered peptide ligands
US7041499B2 (en) 2001-12-12 2006-05-09 University Of North Texas Health Science Center Immuno activation of CS1 receptor in natural killer cells to inhibit tumor cell growth
US6979720B2 (en) 2002-05-03 2005-12-27 E. I. Du Pont De Nemours And Company manufacture of certain cyclic ester oligomers
US20050025763A1 (en) * 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
WO2005037855A2 (en) 2003-10-17 2005-04-28 Pecos Labs, Inc. T cell epitopes useful in a yersinia pestis vaccine and as diagnostic tools and methods for identifying same
ES2393539T3 (es) 2004-03-29 2012-12-26 Abbott Biotherapeutics Corp. Utilización terapéutica de anticuerpos anti-CS1
WO2006028889A2 (en) * 2004-09-02 2006-03-16 Wyeth Systems and methods for protein production
JP2010500370A (ja) * 2006-08-07 2010-01-07 ピーディーエル バイオファーマ，インコーポレイティド 多発性硬化症を処置するための抗ｃｓ１抗体を用いる組成物および方法
HUE029027T2 (en) * 2006-08-07 2017-01-30 Abbvie Biotherapeutics Inc Procedures for Multiple Myeloma Treatment Using HuLuc63 and Bortezomib Combination Therapies
JP2011523560A (ja) 2008-06-02 2011-08-18 ダナ−ファーバー キャンサー インスティテュート インク． Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド
CN105377288B (zh) 2012-11-05 2019-11-15 达纳-法伯癌症研究所股份有限公司 Xbp1、cd138和cs1肽的组合物制备药物的用途

Also Published As

Publication number Publication date
EP2300034B1 (en) 2018-08-08
JP2021054825A (ja) 2021-04-08
US20110159021A1 (en) 2011-06-30
JP7321137B2 (ja) 2023-08-04
JP6796123B2 (ja) 2020-12-02
JP6438100B2 (ja) 2018-12-12
CN102112147B (zh) 2014-05-21
WO2009149021A3 (en) 2010-07-15
US11083783B2 (en) 2021-08-10
CN102112147A (zh) 2011-06-29
US9096681B2 (en) 2015-08-04
JP2015063559A (ja) 2015-04-09
JP2018023397A (ja) 2018-02-15
EP2300034A2 (en) 2011-03-30
US20220031821A1 (en) 2022-02-03
JP2017088613A (ja) 2017-05-25
US20160008444A1 (en) 2016-01-14
JP6224280B2 (ja) 2017-11-01
CA2726804A1 (en) 2009-12-10
JP2019059745A (ja) 2019-04-18
CA3138282A1 (en) 2009-12-10
JP2011523560A (ja) 2011-08-18
EP2300034A4 (en) 2011-11-02
JP6085289B2 (ja) 2017-02-22
WO2009149021A2 (en) 2009-12-10
JP2023134812A (ja) 2023-09-27
EP3384919A1 (en) 2018-10-10

Similar Documents

Publication Publication Date Title
US20220031821A1 (en) Xbp1, cd138, and cs1 peptides
AU2018260912B2 (en) XBP1, CD138, and CS1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions
Kobayashi et al. Identification of helper T-cell epitopes that encompass or lie proximal to cytotoxic T-cell epitopes in the gp100 melanoma tumor antigen
WO2022171032A1 (zh) Ras G13D突变体表位肽及识别Ras G13D突变体的T细胞受体
JP2006518982A (ja) Ｍｈｃｉｉ結合ペプチド
CN116615447A (zh) Ras突变体表位肽及识别ras突变体的t细胞受体
NL2034657B1 (en) RCN1-derived TEIPP neoantigens and uses thereof
WO2005054292A1 (en) Compositions and methods related to a dimeric mhc class i and ii-like molecule (dsmhc i and dsmhc ii)

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140411